PE-Backed WuXi Biologics’ $510M Hong Kong IPO Cheered By Investors

Pan Yue
June 15, 2017 — 06:26 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Ally Bridge China chinese Hillhouse Hillhouse Capital Group Hong Kong insurance investment IPO Legend Manufacturer New York Private Equity revenue Sequoia Sequoia Capital Sequoia Capital China singapore stock exchange technology temasek WuXi Biologics yunfeng

Related News:

Saudi Public Investment Fund (PIF) Reveals Plans to Open New Offices in China

December 13, 2023 — 02:00

Saudi Arabia’s FoFs Jada Backs eWTP Arabia Capital’s Second Fund

December 9, 2023 — 02:30

China To Expand Investment Scope for Its National Social Security Fund

December 8, 2023 — 00:03

Chinese Charitable Foundations Expand Into Alternative Investments To Enhance Returns

November 30, 2023 — 23:50

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

KKR Leads $180 Million Series F Round In Newly-Minted Asian Unicorn Livspace

February 15, 2022 — 03:32

US-Listed Chinese Companies Rush To List In Hong Kong

January 28, 2021 — 07:25

Chinese Investors Jump On The SPAC Bandwagon

January 27, 2021 — 06:02

Franchising and Licensing Asia (FLAsia) 2024